Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Amniotic fluid cathelicidin in PPROM pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis

V. Tambor, M. Kacerovsky, C. Andrys, I. Musilova, H. Hornychova, L. Pliskova, M. Link, J. Stulik, J. Lenco,

. 2012 ; 7 (7) : e41164.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND: Preterm prelabor rupture of membranes (PPROM) complicated by microbial invasion of the amniotic cavity (MIAC) leading to histological chorioamnionitis (HCA) significantly impacts perinatal morbidity. Unfortunately, no well-established tool for identifying PPROM patients threatened by these disorders is available. METHODOLOGY/PRINCIPAL FINDINGS: We performed an unbiased exploratory analysis of amniotic fluid proteome changes due to MIAC and HCA. From among the top five proteins that showed the most profound and significant change, we sought to confirm results concerning cathelicidin (P49913, CAMP_HUMAN), since an ELISA kit was readily available for this protein. In our exploratory proteomic study, cathelicidin showed a ∼6-fold higher concentration in PPROM patients with confirmed MIAC and HCA. We verified significantly higher levels of cathelicidin in exploratory samples (women without both MIAC and HCA: median 1.4 ng/ml; women with both conditions confirmed: median 3.6 ng/ml; p = 0.0003). A prospective replication cohort was used for independent validation and for assessment of cathelicidin potential to stratify women with MIAC leading to HCA from women in whom at least one of these conditions was ruled out. We confirmed the association of higher amniotic fluid cathelicidin levels with MIAC leading to HCA (the presence of both MIAC and HCA: median 3.1 ng/ml; other women: median 1.4 ng/ml; p<0.0001). A cathelicidin concentration of 4.0 ng/ml was found to be the best cut-off point for identifying PPROM women with both MIAC and HCA. When tested on the validation cohort, a sensitivity of 48%, a specificity of 90%, a likelihood ratio of 5.0, and an area under receiver-operating characteristic curve of 71% were achieved for identification of women with MIAC leading to HCA. CONCLUSIONS: Our multi-stage study suggests cathelicidin as a candidate marker that should be considered for a panel of amniotic fluid proteins permitting identification of PPROM women with MIAC leading to HCA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13012595
003      
CZ-PrNML
005      
20130408112438.0
007      
ta
008      
130404s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0041164 $2 doi
035    __
$a (PubMed)22815956
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tambor, Vojtech $u Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
245    10
$a Amniotic fluid cathelicidin in PPROM pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis / $c V. Tambor, M. Kacerovsky, C. Andrys, I. Musilova, H. Hornychova, L. Pliskova, M. Link, J. Stulik, J. Lenco,
520    9_
$a BACKGROUND: Preterm prelabor rupture of membranes (PPROM) complicated by microbial invasion of the amniotic cavity (MIAC) leading to histological chorioamnionitis (HCA) significantly impacts perinatal morbidity. Unfortunately, no well-established tool for identifying PPROM patients threatened by these disorders is available. METHODOLOGY/PRINCIPAL FINDINGS: We performed an unbiased exploratory analysis of amniotic fluid proteome changes due to MIAC and HCA. From among the top five proteins that showed the most profound and significant change, we sought to confirm results concerning cathelicidin (P49913, CAMP_HUMAN), since an ELISA kit was readily available for this protein. In our exploratory proteomic study, cathelicidin showed a ∼6-fold higher concentration in PPROM patients with confirmed MIAC and HCA. We verified significantly higher levels of cathelicidin in exploratory samples (women without both MIAC and HCA: median 1.4 ng/ml; women with both conditions confirmed: median 3.6 ng/ml; p = 0.0003). A prospective replication cohort was used for independent validation and for assessment of cathelicidin potential to stratify women with MIAC leading to HCA from women in whom at least one of these conditions was ruled out. We confirmed the association of higher amniotic fluid cathelicidin levels with MIAC leading to HCA (the presence of both MIAC and HCA: median 3.1 ng/ml; other women: median 1.4 ng/ml; p<0.0001). A cathelicidin concentration of 4.0 ng/ml was found to be the best cut-off point for identifying PPROM women with both MIAC and HCA. When tested on the validation cohort, a sensitivity of 48%, a specificity of 90%, a likelihood ratio of 5.0, and an area under receiver-operating characteristic curve of 71% were achieved for identification of women with MIAC leading to HCA. CONCLUSIONS: Our multi-stage study suggests cathelicidin as a candidate marker that should be considered for a panel of amniotic fluid proteins permitting identification of PPROM women with MIAC leading to HCA.
650    _2
$a dospělí $7 D000328
650    _2
$a plodová voda $x metabolismus $7 D000653
650    _2
$a kationické antimikrobiální peptidy $x biosyntéza $7 D023181
650    _2
$a chorioamnionitida $x diagnóza $x metabolismus $7 D002821
650    _2
$a ELISA $x metody $7 D004797
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a předčasný odtok plodové vody $x diagnóza $x metabolismus $x mikrobiologie $7 D005322
650    _2
$a gestační stáří $7 D005865
650    _2
$a lidé $7 D006801
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a zánět $x metabolismus $7 D007249
650    _2
$a leukocyty $x metabolismus $7 D007962
650    _2
$a pravděpodobnostní funkce $7 D016013
650    _2
$a neutrofily $x metabolismus $7 D009504
650    _2
$a peptidy $x chemie $7 D010455
650    _2
$a těhotenství $7 D011247
650    _2
$a proteomika $x metody $7 D040901
650    _2
$a ROC křivka $7 D012372
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a trypsin $x chemie $7 D014357
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kacerovsky, Marian $u -
700    1_
$a Andrýs, Ctirad $u - $7 mzk2008430528
700    1_
$a Musilova, Ivana $u -
700    1_
$a Hornychova, Helena $u -
700    1_
$a Pliskova, Lenka $u -
700    1_
$a Link, Marek $u -
700    1_
$a Stulik, Jiri $u -
700    1_
$a Lenco, Juraj $u -
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 7, č. 7 (2012), s. e41164
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22815956 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20130408112705 $b ABA008
999    __
$a ok $b bmc $g 975793 $s 810876
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 7 $c 7 $d e41164 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20130404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...